There are cases in which inhibition of PGAM5 can be of therapeutic value, not only for cancer but also for other pathologies, through the use of LFHP-1c, a new PGAM5 inhibitor, which, in this case, allowed for enhanced activation of NRF2, with promising results for brain ischemic stroke by counteracting ischemia-induced Blood–Brain Barrier (BBB) disruption [111]. Here, NFE2L2 is linked to cancer.